Get the Stockscreener App
18.02
7.84%
1.31
After Hours:
17.95
-0.07
-0.39%
Moonlake Immunotherapeutics stock is traded at $18.02, with a volume of 707.78K.
It is up +7.84% in the last 24 hours and down -1.10% over the past month.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
See More
Previous Close:
$16.71
Open:
$16.93
24h Volume:
707.78K
Relative Volume:
0.38
Market Cap:
$1.29B
Revenue:
-
Net Income/Loss:
$-230.32M
P/E Ratio:
-5.1108
EPS:
-3.5259
Net Cash Flow:
$-196.04M
1W Performance:
+11.03%
1M Performance:
-1.10%
6M Performance:
-68.04%
1Y Performance:
-54.58%
1-Day Range:
$16.88
$18.03
1-Week Range:
$16.03
$18.03
52-Week Range:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Name
Moonlake Immunotherapeutics
Sector
Industry
Phone
41 41 510 8022
Address
DORFSTRASSE 29, ZUG
Compare MLTX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
18.02 | 1.20B | 0 | -230.32M | -196.04M | -3.5259 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-19-26 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Jan-15-26 | Downgrade | Goldman | Neutral → Sell |
| Jan-09-26 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-02-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-01-25 | Downgrade | Goldman | Buy → Neutral |
| Sep-30-25 | Downgrade | Citigroup | Buy → Neutral |
| Sep-30-25 | Downgrade | Wolfe Research | Outperform → Underperform |
| Sep-29-25 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-29-25 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-29-25 | Downgrade | Stifel | Buy → Hold |
| Jul-28-25 | Initiated | Rothschild & Co Redburn | Neutral |
| May-19-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-17-25 | Upgrade | Goldman | Neutral → Buy |
| Nov-05-24 | Resumed | Wedbush | Outperform |
| Aug-26-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Nov-02-23 | Initiated | Stifel | Buy |
| Sep-14-23 | Downgrade | Bryan Garnier | Buy → Neutral |
| Aug-31-23 | Initiated | Needham | Buy |
| Jun-15-23 | Initiated | Barclays | Equal Weight |
| May-01-23 | Initiated | Guggenheim | Buy |
| Mar-22-23 | Initiated | Wedbush | Outperform |
| Mar-09-23 | Initiated | BTIG Research | Buy |
| Feb-14-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-02-23 | Initiated | Bryan Garnier | Buy |
| Nov-11-22 | Initiated | Jefferies | Buy |
| Aug-25-22 | Initiated | SVB Leerink | Outperform |
| Jul-21-22 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Initiated | Cowen | Outperform |
View All
Moonlake Immunotherapeutics Stock (MLTX) Latest News
Breakout Watch: What is the Moat Score of MoonLake Immunotherapeutics2026 Action & Fast Gaining Stock Reports - baoquankhu1.vn
MoonLake stock soars as biotech fund reloads, takeover chatter ignites - MSN
MoonLake surges 65% after InvestingPro Fair Value identifies opportunity By Investing.com - Investing.com Australia
Wolfe Research upgrades Moonlake stock rating on positive 2026 outlook By Investing.com - Investing.com India
MoonLake upgraded to Outperform from Underperform at Wolfe Research - TipRanks
HLXC,MLTX Volatility & Greeks - Finviz
MLTX Upgraded to 'Outperform' by Wolfe Research with Target Pric - GuruFocus
HLXC,MLTX Forecast, Target Price - Finviz
This APA Analyst Is No Longer Bearish; Here Are Top 2 Upgrades For Monday - Benzinga
Wolfe Research Upgrades MoonLake Immunotherapeutics(MLTX.US) to Buy Rating, Announces Target Price $24 - 富途牛牛
Wolfe Research Upgrades MoonLake Immunotherapeutics (NASDAQ:MLTX) to "Outperform" - MarketBeat
Wolfe Research upgrades Moonlake stock rating on positive 2026 outlook - Investing.com
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? - AOL.com
MoonLake upgraded at Rothschild & Co Redburn citing potential FDA nod for lead drug - MSN
MoonLake cut to sell at Goldman Sachs on risks to lead asset’s approval - MSN
Citi Maintains MoonLake Immunotherapeutics(MLTX.US) With Sell Rating, Maintains Target Price $6 - 富途牛牛
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Cormorant’s Large Share Purchase - simplywall.st
Technical Reactions to MLTX Trends in Macro Strategies - Stock Traders Daily
MLTX Stock Chart | MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ:MLTX) - ChartMill
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up After Analyst Upgrade - MarketBeat
Rothschild & Co Redburn Upgrades MoonLake Immunotherapeutics(MLTX.US) to Buy Rating, Cuts Target Price to $40 - 富途牛牛
MoonLake Immunotherapeutics (NASDAQ:MLTX) Upgraded by Rothschild & Co Redburn to Buy Rating - MarketBeat
MoonLake upgraded to Buy from Neutral at Rothschild & Co Redburn - TipRanks
Rothschild Redburn upgrades Moonlake stock on regulatory clarity - Investing.com
Rothschild & Co upgrades MoonLake Immunotherapeutics (MLTX) - MSN
MoonLake Immunotherapeutics (MLTX) price target increased by 11.25% to 22.30 - MSN
Caitong International Asset Management Co. Ltd Increases Holdings in MoonLake Immunotherapeutics $MLTX - MarketBeat
Earnings Beat: Will MoonLake Immunotherapeutics be affected by tariffs2026 EndofYear Setup & Entry Point Confirmation Signals - baoquankhu1.vn
RBC Capital Downgrades MoonLake Immunotherapeutics (MLTX) - MSN
This fund acquired $28 million worth of a struggling immunotherapy stock last quarter. What important information should long-term investors consider? - Bitget
Boxer Capital Management LLC Acquires New Holdings in MoonLake Immunotherapeutics $MLTX - MarketBeat
Avoro Capital Advisors LLC Cuts Stock Position in MoonLake Immunotherapeutics $MLTX - MarketBeat
TD Cowen Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating - 富途牛牛
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
MLTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (MLTX), Sarepta Therapeutics (SRPT) and vTv Therapeutics (VTVT) - The Globe and Mail
Clear Street Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $70 - 富途牛牛
Clear Street raises Moonlake stock price target on IL-17 data - Investing.com Nigeria
MoonLake price target raised to $70 from $45 at Clear Street - TipRanks
Clear Street raises Moonlake stock price target on IL-17 data By Investing.com - Investing.com Australia
How Investors Are Reacting To MoonLake Immunotherapeutics (MLTX) Widening Annual Net Loss Amid Share Price Gains - simplywall.st
Trading the Move, Not the Narrative: (MLTX) Edition - Stock Traders Daily
Rhenman & Partners Asset Management AB Buys 162,000 Shares of MoonLake Immunotherapeutics $MLTX - MarketBeat
MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout - MSN
Moonlake Immunotherapeutics Stock (MLTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):